Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord BiotechBOM:543960 +0.67%68 EBITDA Margin % is 41.00% as of Mar. 2026, which is 12% below its 10-year median of 46.57. GuruFocus rates BOM:543960 with a GF Score™ of 68/100 and a GF Value™ of ₹1,666.31 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 939 Biotechnology companies, Concord Biotech ranks better than 92.12% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Concord Biotech's EBITDA for the
three
months ended in Mar. 2026 was ₹1,337 Mil. Concord Biotech's Revenue for the
three
months ended in Mar. 2026 was ₹3,261 Mil. Therefore, Concord Biotech's EBITDA margin for the quarter that ended in Mar. 2026 was 41.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Concord Biotech EBITDA Margin % Related Terms
Concord Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Concord Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543960 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Concord Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Concord Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Biotech (BOM:543960) has a EBITDA Margin % of 41.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Concord Biotech and its competitors. This is 12% below median its historical median of 46.57. Over the past decade, Concord Biotech's EBITDA Margin % has ranged from 39.76 to 56.44. According to the industry distribution chart, Concord Biotech ranks #74 out of 939 companies in the Biotechnology industry, placing it in the top 7.9%.
Is Concord Biotech's EBITDA Margin % too high?
Concord Biotech's current EBITDA Margin % of 41.00% is 12% below median its 10-year median of 46.57. Over the past 10 years, this metric has ranged from a low of 39.76 to a high of 56.44. Based on the distribution chart, Concord Biotech ranks #74 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Concord Biotech has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #74 out of 939 companies for EBITDA Margin %. This places Concord Biotech in the top 8% of its industry — outperforming the majority of peers. Historically, Concord Biotech's own EBITDA Margin % has ranged from 39.76 to 56.44 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Concord Biotech and its competitors. Concord Biotech's current EBITDA Margin % is 41.00%, which is 12% below median its own 10-year median of 46.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,666.31, compared to a current price of ₹1,257.00 — trading 24.6% below its estimated fair value. The current EBITDA Margin % is 41.00%, which is 12% below median its 10-year median of 46.57. Concord Biotech's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current EBITDA Margin % is 41.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (BOM:543960) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,257.00 is trading 24.6% below its estimated GF Value™ of ₹1,666.31.
GuruFocus considers Concord Biotech to be Modestly Undervalued.
Key valuation signals for BOM:543960:
EBITDA Margin %: 41.00% (12% below median its 10-year median of 46.57)
GF Value™: ₹1,666.31 vs. price of ₹1,257.00 (24.6% below fair value)
No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
68GF Score
Get the complete analysis for BOM:543960
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543960 has been successfully added to your 
